This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImmunoGen, Inc. Announces Overall Survival Data Reported For Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial

Stock quotes in this article: IMGN

ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA. Trastuzumab emtansine is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group, and utilizes ImmunoGen’s TAP technology with the trastuzumab antibody. Genentech and Roche have applied for marketing approval of trastuzumab emtansine in the US and Europe, respectively.

The EMILIA trial was designed to evaluate trastuzumab emtansine for the treatment of patients with metastatic HER2-positive breast cancer who have previously received trastuzumab (Herceptin®) and a taxane. Patients enrolled were randomized to treatment either with trastuzumab emtansine – used alone – or with lapatinib (Tykerb®) plus capecitabine (Xeloda®), standard-of-care in this setting. EMILIA progression-free survival (PFS) and tolerability findings were previously reported at the American Society of Clinical Oncology (ASCO) annual meeting in June 2012: patients treated with trastuzumab emtansine had a significant improvement in PFS (hazard ratio=0.65, p<0.0001) and experienced fewer Grade 3 or greater (severe) adverse events (40.8 percent vs. 57.0 percent) than those treated with standard-of-care. 1 PFS and OS are co-primary endpoints of the EMILIA trial.

The OS data reported today showed that the risk of death was reduced by 32 percent for patients who received trastuzumab emtansine compared to those who received standard-of-care (hazard ratio=0.68, p=0.0006). Patients treated with trastuzumab emtansine survived a median of 5.8 months longer than those who received Tykerb plus Xeloda: median OS was 30.9 months for patients receiving trastuzumab emtansine versus 25.1 months for patients receiving standard-of-care.

“We’re thrilled that trastuzumab emtansine provided this significant overall survival benefit,” commented Daniel Junius, President and CEO. “We believe trastuzumab emtansine is an important new medicine and are hopeful it will advance into the hands of practicing oncologists as rapidly as possible.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,782.24 -260.66 -1.53%
S&P 500 1,946.93 -25.36 -1.29%
NASDAQ 4,421.1990 -72.1910 -1.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs